These immune checkpoints have been widely considered to be related to the immune escape of tumor cells and can promote the progression of ovarian cancer, and treatment options for these immune checkpoints, such as anti-PD-L1 therapy, can significantly improve the prognosis of patients with recurrent ovarian cancer. This evidence concerns the gene CD274 and neoplasm.